Endonovo Therapeutics, Inc. (ENDV)
Endonovo Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Woodland Hills, CA, US. The stock last traded at $0.00, down 0.00% on the session, giving a market capitalisation of $31,875. On trailing twelve-month figures it carries a trailing P/E of -0.20, a net margin of 0.0%. Its beta of -8.78 implies it has historically moved less than the broad market.
Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.
Endonovo Therapeutics, Inc. is most often compared with the following Healthcare names: